Potential anaphylactic shock with abciximab readministration.
A 46-year-old woman developed an anaphylactic reaction during percutaneous coronary intervention after she was pretreated with prednisone and diphenhydramine for a known allergy to iodine. She developed pruritus, edema, and nausea, which were followed by bradycardia and shock, minutes after administration of a bolus and standard-dose infusion of abciximab. The reaction was treated successfully with epinephrine, methoxamine, hydrocortisone, atropine, furosemide, sodium bicarbonate, diphenhydramine, and ranitidine.
Pharand
Chantal
C
Research Centre, the Department of Pharmacy, Hĵpital du Sacré-Coeur de Montreal, Quebec, Canada. pharandc@crhsc.umontreal.ca
Palisaitis
Donald A
DA
Hamel
Denis
D
D000077284:Abciximab; D000707:Anaphylaxis / Q000139:chemically induced* / Q000188:drug therapy; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001919:Bradycardia / Q000139:chemically induced; D004155:Diphenhydramine / Q000627:therapeutic use; D004487:Edema / Q000139:chemically induced; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010359:Patient Readmission; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011241:Prednisone / Q000627:therapeutic use; D011537:Pruritus / Q000139:chemically induced
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D004155:Diphenhydramine; D011241:Prednisone; D000077284:Abciximab